89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Phase 2
55
about 7.3 years
18+
1 site in TX
What this study is about
Researchers are testing the use of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with kidney cancer. The trial will assess how well this imaging technique correlates with PD-L1 expression and response to immune checkpoint inhibitor therapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 89Zr-DFO-Atezolizumab
- 2.Undergo Positron Emission Tomography/Computed Tomography
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
injection (Injection)
Primary: Correlation between 89Zr-DFO-Atezolizumab and PD-L1, Correlation between 89Zr-DFO-Atezolizumab and anti-PD1/PD-L1 therapy
imaging
Oncology